Development of cardiovascular bypass grafts: Endothelialization and applications of nanotechnology

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 9, 2008, Pages 1259-1277

  de Mel, Achala ^a   Bolvin, Capucine ^a,b   Edirisinghe, Mohan ^c   Hamilton, George ^a,d   Seifalian, Alexander M ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antithrombogenic; Endothelial cell; Endothelialization; Intimal hyperplasia; Nanocomposite; Nanotechnology; Progenitor stem cell; Vascular bypass graft

Indexed keywords

AGL 2043; ALBUMIN; ALENDRONIC ACID; ANTISENSE OLIGONUCLEOTIDE; BIOMATERIAL; CERAMIDE; COPOLYMER; DEXAMETHASONE; DOXORUBICIN; GROWTH FACTOR; HYALURONIC ACID; LIPOSOME; MACROGOL; MOLECULAR SCAFFOLD; NANOCOATING; NANOCOMPOSITE; NANOPARTICLE; NANOTUBE; NUCLEIC ACID; PACLITAXEL; POLYELECTROLYTE; POLYGLACTIN; POLYMER; POLYPROPYLENE; POLYVINYL ALCOHOL; RAPAMYCIN; SCAFFOLD PROTEIN; SMALL INTERFERING RNA; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTERY INTIMA PROLIFERATION; BIODEGRADABILITY; BYPASS SURGERY; CARDIOVASCULAR SURGERY; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CRYOPRESERVATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOTHELIALIZATION; EXTRACELLULAR MATRIX; GENE THERAPY; GENE TRANSFER; HUMAN; IN SITU HYBRIDIZATION; MECHANICAL STIMULATION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RESTENOSIS; REVIEW; SURGICAL TECHNIQUE; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM;

CARDIOVASCULAR DISEASES; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CORONARY ARTERY BYPASS; ENDOTHELIUM, VASCULAR; HUMANS; LEG; NANOTECHNOLOGY; STEM CELLS;

EID: 55449102797     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.9.1259     Document Type: Review

References (158)

1. Urban P, De Benedetti E. Thrombosis: the last frontier of coronary stenting? Lancet 369(9562), 619-621 (2007).
2. Hannan E, Racz MJ, Walford G et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N. Engl. J. Med. 352 (21), 2174-2183 (2005).
3. Seung KB, Park DW, Kim YH et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N. Engl. J. Med. 358 (17), 1781-1792 (2008).
4. Kannan RY, Salacinski HJ, Butler PE, Hamilton G, Seifalian AM. Current status of prosthetic bypass grafts: a review. J. Biomed. Mater. Res. B Appl. Biomater. 74(1), 570-581 (2005).
5. Xue L, Greisler HP. Biomaterials in the development and future of vascular grafts. J. Vasc. Surg. 37(2), 472-480 (2003).
6. Stewart SF, Lyman DJ. Effects of a vascular graft/natural artery compliance mismatch on pulsatile flow. J. Biomech. 25(3), 297-310 (1992).
7. Sarkar S, Schmitz-Rixen T, Hamilton G, Seifalian AM. Achieving the ideal properties for vascular bypass grafts using a tissue engineered approach: a review. Medical Med. Biol. Eng. Comput. 45(4), 327-336 (2007).
8. Noh H, Vogler EA. Volumetric interpretation of protein adsorption: competition from mixtures and the Vroman effect. Biomaterials 28(3), 405-422 (2007).
9. Hasirci V, Vrana E, Zorlutuna P et al. Nanobiomaterials: a review of the existing science and technology, and new approaches. J. Biomater. Sci. Polym. Ed. 17(11), 1241-1268 (2006).
10. Miller DC, Webster TJ, Haberstroh KM. Technological advances in nanoscale biomaterials: the future of synthetic vascular graft design. Expert Rev. Med. Devices 1(2), 259-268 (2004).
11. Mironov V, Kasyanov V, Markwald RR. Nanotechnology in vascular tissue engineering: from nanoscaffolding towards rapid vessel biofabrication. Trends Biotechnol. 26(6), 338-344 (2008).
12. Seifalian AM, Salacinski HJ, Tiwari A, Edwards A, Bowald S, Hamilton G. In vivo biostability of a poly(carbonate-urea) urethane graft. Biomaterials 24 (14), 2549-2557 (2003).
13. Sarkar S, Salacinski HJ, Hamilton G, Seifalian AM. The mechanical properties of infrainguinal vascular bypass grafts: their role in influencing patency. Eur. J Vasc. Endovasc. Surg. 31(6), 627-636 (2006).
14. Kannan RY, Salacinski HJ, De GJ et al. The antithrombogenic potential of a polyhedral oligomeric silsesquioxane (POSS) nanocomposite. Biomacromolecules 7(I), 215-223 (2006).
15. Kannan RY, Salacinski HJ, Sales KM, Butler PE, Seifalian AM. The endothelialization of polyhedral oligomeric silsesquioxane nanocomposites: an in vitro study. Cell Biochem. Biophys. 45(2), 129-136 (2006).
16. Punshon G, Sales KM, Vara DS, Hamilton G, Seifalian AM. Assessment of the potential of progenitor stem cells extracted from human peripheral blood for seeding a novel vascular graft material. Cell Prolif. 41(2), 321-335 (2008).
17. Hoenig MR, Campbell GR, Campbell JH. Vascular grafts and the endothelium. Endothelium 13(6), 385-401 (2006).
18. Zilla P, von OU, Deutsch M. The endothelium: a key to the future. J. Card. Surg. 8(1), 32-60 (1993).
19. Salacinski HJ, Tai NR, Punshon G, Giudiceandrea A, Hamilton G, Seifalian AM. Optimal endothelialisation of a new compliant poly(carbonate-urea) urethane vascular graft with effect of physiological shear stress. Eur. J. Vasc. Endovasc. Surg. 20(4), 342-352 (2000).
20. Herring M, Gardner A, Glover J. Single-staged technique for seeding vascular grafts with autogenous endothelium. Surgery 84(4),498-504 (1978).
21. Tiwari A, Salacinski HJ, Hamilton G, Seifalian AM. Tissue engineering of vascular bypass grafts: role of endothelial cell extraction. Eur. J. Vasc. Endovasc. Surg. 21(3), 193-201 (2001).
22. Kaushal S, Amiel GE, Guleserian KJ et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat. Med. 7(9), 1035-1040 (2001).
23. DiMuzio P, Tulenko T. Tissue engineering applications to vascular bypass graft development: the use of adipose-derived stem cells. J. Vasc. Surg. 45 (Suppl.A), A99-A103 (2007).
24. Bordenave L, Fernandez P, Remy-Zolghadri M, Villars S, Daculsi R, Midy D. In vitro endothelialized ePTFE prostheses: clinical update 20 years after the first realization. Clin. Hemorheol. Microcirc. 33(3), 227-234 (2005).
25. Rotmans JI, Heyligers JM, Verhagen HJ et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 112(1), 12-18 (2005).
26. Silber S. Capturing circulating endothelial progenitor cells: a new concept tested in the HEAING studies. Minerva Cardioangiol. 54(1), 1-3 (2006).
27. Vara DS, Salacinski HJ, Kannan RY, Bordenave L, Hamilton G, Seifalian AM. Cardiovascular tissue engineering: state of the art. Pathol. Biol. (Paris) 53(10), 599-612 (2005).
28. Wu B, Gerlitz B, Grinnell BW, Meyerhoff ME. Polymeric coatings that mimic the endothelium: combining nitric oxide release with surface-bound active thrombomodulin and heparin. Biomaterials 28(28), 4047-4055 (2007).
29. Weinberg CB, Bell E. A blood vessel model constructed from collagen and cultured vascular cells. Science 231(4736), 397-400 (1986).
30. Girton TS, Oegema TR, Grassl ED, Isenberg BC, Tranquillo RT. Mechanisms of stiffening and strengthening in media-equivalents fabricated using glycation. J. Biomech. Eng. 122(3), 216-223 (2000).
31. Isenberg BC, Tranquillo RT. Long-term cyclic distention enhances the mechanical properties of collagen-based media-equivalents. Ann. Biomed. Eng. 31(8), 937-949 (2003).
32. Isenburg JC, Simionescu DT, Vyavahare NR. Elastin stabilization in cardiovascular implants: improved resistance to enzymatic degradation by treatment with tannic acid. Biomaterials 25(16), 3293-3302 (2004).
33. Thakrar RR, Patel VP, Hamilton G, Fuller BJ, Seifalian AM. Vitreous cryopreservation maintains the viscoelastic property of human vascular grafts. FASEB J. 20(7), 874-881 (2006).
34. Bader A, Steinhoff G, Strobl K et al. Engineering of human vascular aortic tissue based on a xenogeneic starter matrix. Transplantation 70(1), 7-14 (2000).
35. Dardik H, Wengerter K, Qin F et al. Comparative decades of experience with glutaraldehyde-tanned human umbilical cord vein graft for lower limb revascularization: an analysis of 1275 cases. J. Vasc. Surg. 35(1), 64-71 (2002).
36. Kobayashi T, Cooper DK. Anti-Gal, α-Gal epitopes, and xenotransplantation. Subcell. Biochem. 32, 229-257 (1999).
37. Spark JI, Yeluri S, Derham C et al. Incomplete cellular depopulation may explain the high failure rate of bovine ureteric grafts. Br. J. Surg. 95(5), 582-585 (2008).
38. Poh M, Boyer M, Solan A et al. Blood vessels engineered from human cells. Lancet 365(9477), 2122-2124 (2005).
39. Cheng ST, Chen ZF, Chen GQ. The expression of cross-linked elastin by rabbit blood vessel smooth muscle cells cultured in polyhydroxyalkanoate scaffolds. Biomaterials 29(31), 4187-94 (2008).
40. Motlagh D, Allen J, Hoshi R, Yang J, Lui K, Ameer G. Hemocompatibility evaluation of poly(diol citrate) in vitro for vascular tissue engineering. J. Biomed. Mater. Res. A 82(4), 907-916 (2007).
41. Gao J, Crapo P, Nerem R, Wang Y. Coexpression of elastin and collagen leads to highly compliant engineered blood vessels. J. Biomed. Mater. Res. A 85(4), 1120-1128 (2008).
42. Gong Z, Niklason E. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs). FASEB J. 22(6), 1635-1648 (2008).
43. Lepidi S, Abatangelo G, Vindigni V et al. In vivo regeneration of small-diameter (2 mm) arteries using a polymer scaffold. FASEB J. 20(1), 103-105 (2006).
44. Remuzzi A, Mantero S, Colombo M et al. Vascular smooth muscle cells on hyaluronic acid: culture and mechanical characterization of an engineered vascular construct. Tissue Eng. 10(5-6), 699-710 (2004).
45. Nieponice A, Soletti, Guan J et al. Development of a tissue-engineered vascular graft combining a biodegradable scaffold, muscle-derived stem cells and a rotational vacuum seeding technique, Biomaterials 29(7), 825-833 (2008).
46. Matsumura G, Hibino N, Ikada Y, Kurosawa H, Shin'oka T. Successful application of tissue engineered vascular autografts: clinical experience. Biomaterials 24(13), 2303-2308 (2003).
47. Baguneid MS, Seifalian AM, Salacinski HJ, Murray D, Hamilton G, Walker MG. Tissue engineering of blood vessels. Br. J. Surg. 93(3), 282-290 (2006).
48. Baguneid M, Murray D, Salacinski HJ et al. Shear-stress preconditioning and tissue-engineering-based paradigms for generating arterial substitutes. Biotechnol. Appl. Biochem. 39(Pt 2), 151-157 (2004).
49. L'Heureux N, Dusserre N, Konig G et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nat. Med. 12(3), 361-365 (2006).
50. L'Heureux N, McAllister TN, de la Fuente M. Tissue-engineered blood vessel for adult arterial revascularization. N. Engl. J. Med. 357(14), 1451-1453 (2007).
51. Campbell JH, Efendy J, Campbell GR. Novel vascular graft grown within recipient's own peritoneal cavity. Circ. Res. 85(12), 1173-1178 (1999).
52. Cao Y, Zhang B, Croll T et al. Engineering tissue tubes using novel multilayered scaffolds in the rat peritoneal cavity. J. Biomed. Mater. Res. A PMID: 18200539 (2008) (Epub ahead of print).
53. Meinhart JG, Deutsch M, Fischlein T, Howanietz N, Froschl A, Zilla P. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Ann. Thorac. Surg. 71(5 Suppl.), S327-S331 (2001).
54. Laube HR, Duwe J, Rutsch W, Konertz, W. Clinical experience with autologous endothelial cell-seeded polytetrafluoroethylene coronary artery bypass grafts. J. Thorac. Cardiovasc. Surg. 120(1), 134-141 (2000).
55. Gabbieri D, Dohmen PM, Koch C, Lembcke A, Rutsch W, Konertz W. Aortocoronary endothelial cell-seeded polytetrafluoroethylene graft: 9-year patency. Ann. Thorac. Surg. 83(3), 1166-1168 (2007).
56. Rashid ST, Fuller B, Hamilton G, Seifalian AM. Tissue engineering of a hybrid bypass graft for coronary and lower limb bypass surgery. FASEB J. 22(6), 2084-2089 (2008).
57. Tai NR, Giudiceandrea A, Salacinski HJ, Seifalian AM, Hamilton G. In vivo femoropopliteal arterial wall compliance in subjects with and without lower limb vascular disease. J. Vasc. Surg. 30(5), 936-945 (1999).
58. Kannan RY, Salacinski HJ, Butler PE, Seifalian AM. Polyhedral oligomeric silsesquioxatie nanocomposites: the next generation material for biomedical applications. Acc. Chem. Res. 38(11), 879-84 (2005).
59. Kannan RY, Salacinski HJ, Edirisinghe MJ, Hamilton G, Seifalian AM. Polyhedral oligomeric silsequioxane-polyurethane nanocomposite microvessels for an artificial capillary bed. Biomaterials 27(26), 4618-4626 (2006).
60. Kannan RY, Salacinski HJ, Odlyha M, Butler PE, Seifalian AM. The degradative resistance of polyhedral oligomeric silsesquioxane nanocore integrated polyurethanes: an in vitro study. Biomaterials 27(9), 1971-1979 (2006).
61. Gopakumar TG, Xanthos M, Xanthos M. Effect of nanofillers on the properties of flexible protective polymer coatings. Polymer Composites 27(4), 368-380 (2006).
62. Gupta A, Seifalian AM, Ahmad Z, Edirisinghe MJ, Winslet MC. Novel electrohydrodynamic printing of nanocomposite biopolymer scaffolds. J. Bioact. Compat. Polym. 22(3), 265-280 (2007).
63. Kidane AG, Edirisinghe MJ, Bonhoeffer P, Seifalian AM. Flow behaviour of a POSS biopolymer solution. Biorheology 44(4), 265-272 (2007).
64. Kotch FW, Raines RT. Self-assembly of synthetic collagen triple helices. Proc. Natl Acad. Sci. USA 103(9), 3028-3033 (2006).
65. Woolfson DN, Ryadnov MG. Peptide-based fibrous biomaterials: some things old, new and borrowed. Curr. Opin. Chem. Biol. 10(6), 559-567 (2006).
66. Miao M, Cirulis JT, Lee S, Keeley FW. Structural determinants of cross-linking and hydrophobic domains for self-assembly of elastin-like polypeptides. Biochemistry 44(43), 14367-14375 (2005).
67. Bellingham CM, Lillie MA, Gosline JM et al. Recombinant human elastin polypeptides self-assemble into biomaterials with elastin-like properties. Biopolymers 70(4), 445-455 (2003).
68. Gauba V, Hartgerink JD. Self-assembled heterotrimeric collagen triple helices directed through electrostatic interactions. J. Am. Chem. Soc. 129(9), 2683-2690 (2007).
69. Endo M, Koyama S, Matsuda Y, Hayashi T, Kim YA. Thrombogenicity and blood coagulation of a microcatheter prepared from carbon nanotube - nylon-based composite. Nano Lett. 5(1), 101-105 (2005).
70. Koyama S, Haniu H, Osaka K et al. Medical application of carbon-nanotube-filled nanocomposites: the microcatheter. Small 2(12), 1406-1411 (2006).
71. Kim JY, Khang D, Lee JE, Webster TJ. Decreased macrophage density on carbon nanotube patterns on polycarbonate urethane. J. Biomed. Mater. Res. A (2008).
72. Hurt RH, Monthioux M, Kane A. Toxicology of carbon nanomaterials: status, trends, and perspectives on the special issue. Carbon 44(6), 1028-1033 (2006).
73. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc. Res. 78 (3), 413-421 (2008).
74. Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardiovasc. Interv. 70 (4), 477-484 (2007).
75. Kawamoto A, Losordo DW. Endothelial progenitor cells for cardiovascular regeneration. Trends Cardiovasc. Med. 18(1), 33-37 (2008).
76. Adams B, Xiao Q, Xu Q. Stem cell therapy for vascular disease. Trends Cardiovasc. Med. 17(7), 246-251 (2007).
77. Hwang NS, Varghese S, Elisseeff J. Controlled differentiation of stem cells. Adv. Drug Deliv. Rev. 60(2), 199-214 (2008).
78. Dawson E, Mapili G, Erickson K, Taqvi S, Roy K. Biomaterials for stem cell differentiation. Adv. Drug Deliv. Rev. 60(2), 215-228 (2008).
79. Saha K, Pollock JF, Schaffer DV, Healy KE. Designing synthetic materials to control stem cell phenotype. Curr. Opin. Chem. Biol. 11(4), 381-387 (2007).
80. Chai C, Leong KW. Biomaterials approach to expand and direct differentiation of stem cells. Mol. Ther. 15(3), 467-480 (2007).
81. Alobaid N, Salacinski HJ, Sales KM et al. Nanocomposite containing bioactive peptides promote endothelialisation by circulating progenitor cells: an in vitro evaluation. Eur. J. Vasc. Endovasc. Surg. 32(1), 76-83 (2006).
82. de Mel A, Jell G, Stevens M, Seifalian AM. Biofunctionalisation of biomaterials for accelerated in situ endothelialization: a review. Biomacromolecules (2008)
83. Miller DC, Thapa A, Haberstroh KM, Webster TJ. Endothelial and vascular smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface features. Biomaterials 25(1), 53-61 (2004).
84. Miller DC, Haberstroh KM, Webster TJ. Mechanism(s) of increased vascular cell adhesion on nanostructured poly(lactic-co-glycolic acid) films. J. Biomed. Mater. Res. A. 73A(4), 476-484 (2005).
85. Miller DC, Haberstroh KM, Webster TJ. PLGA nanometer surface features manipulate fibronectin interactions for improved vascular cell adhesion. J. Biomed. Mater. Res. A 81A(3), 678-684 (2007).
86. Pham. QP, Sharma U, Mikos AG. Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng. 12 (5), 1197-1211 (2006).
87. Murugan R, Ramakrishna S. Nano-featured scaffolds for tissue engineering: a review of spinning methodologies. Tissue Eng. 12(3), 435-447 (2006).
88. Norman JJ, Desai TA. Methods for fabrication of nanoscale topography for tissue engineering scaffolds. Ann. Biomed. Eng. 34(1), 89-101 (2006).
89. Barnes CP, Sell SA, Boland ED, Simpson DG, Bowlin G. Nanofiber technology: designing the next generation of tissue engineering scaffolds. Adv. Drug Deliv. Rev. 59(14), 1413-1433 (2007).
90. Lee SJ, Yoo JJ, Lim GJ, Atala A, Stitzel J. In vitro evaluation of electrospun nanofiber scaffolds for vascular graft application. J. Biomed. Mater. Res. A 83(4), 999-1008 (2007).
91. Stankus JJ, Soletti L, Fujimoto K, Hong Y, Vorp DA, Wagner WR. Fabrication of cell microintegrated blood vessel constructs through electrohydrodynamic atomization. Biomaterials 28(17), 2738-2746 (2007).
92. Xu J, Zhou X, Ge H et al. Endothelial cells anchoring by functionalized yeast polypeptide. J. Biomed. Mater. Res. A PMID: 18228253 (2008) (Epub ahead of print).
93. He W, Ma Z, Teo WE et al. Tubular nanofiber scaffolds for tissue engineered small-diameter vascular grafts. J. Biomed. Mater. Res. A PMID: 18491396 (2008) (Epub ahead of print).
94. Matsusaki M, Sakaguchi H, Serizawa T, Akashi M. Controlled release of vascular endothelial growth factor from alginate hyd rogels nano-coated with polyelectrolyte multilayer films. J. Biomater. Sci. Polym. Ed. 18(6), 775-783 (2007).
95. Huang M, Vitharana SN, Peek J, Coop T, Berkland C. Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor. Biomacromolecules 8(5), 1607-1614 (2007).
96. Huang M, Berkland C. Controlled release of Repifermin(R) from polyelectrolyte complexes stimulates endothelial cell proliferation. J. Pharm. Sci. PMID: 18425807 (2008) (Epub ahead of prini).
97. Boura C, Muller S, Vander D et al. Endothelial cell - interactions with polyelectrolyte multilayer films. Biomaterials 26(22), 4568-4575 (2005).
98. Zhong Y, Whittington CF, Haynie DT. Stimulated release of small molecules from polyelectrolyte multilayer nanocoatings. Chem. Commun. (Camb.) 14(14), 1415-1417 (2007).
99. Ahmad Z, Zhang HB, Farook U, Edirisinghe M, Stride E, Colombo P. Generation of multilayered structures for biomedical applications using a novel tri-needle coaxial device and electrohydrodynamic flow. J. R. Soc. Interface 5 (27), 1255-1261 (2008).
100. Cohen-Sela E, Rosenzweig O, Gao J et al. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J. Control Release 113 (1), 23-30 (2006).
101. Lim HJ, Nam HY, Lee BH, Kim DJ, Ko JY, Park JS. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts. Biotechnol. Prog. 23(3), 693-697 (2007).
102. Perea H, Aigner J, Heverhagen JT, Hopfner U, Wintermantel E. Vascular tissue engineering with magnetic nanoparticles: seeing deeper. J. Tissue Eng. Regen. Med. 1(4), 318-321 (2007).
103. Chen S, Hilcove S, Ding S. Exploring stem cell biology with small molecules. Mol. Biosyst. 2(1), 18-24 (2006).
104. Schugar RC, Robbins PD, Deasy BM. Small molecules in stem cell self-renewal and differentiation. Gene Ther. 15(2), 126-135 (2008).
105. Ding S, Schultz PG. A role for chemistry in stem cell biology. Nat. Biotechnol. 22(7), 833-840 (2004).
106. Xu YY, Li YJ, Guan H et al. The effect of vascular endothelia growth factor encapsulated in nanoparticles on chronic limb ischemia. Zhonghua Wai Ke Za Zhi 42(1), 58-61 (2004).
107. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors - biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Card. 49 (10), 1015-1026 (2007).
108. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine 1(1), 22-30 (2005).
109. Zweers M, Engbers GH, Grijpma DW, Feijen J. Release of anti-restenosis drugs from poly(ethylene oxide)-poly(D-lactic-co-glycolic acid) nanoparticles. J. Control. Release 114(3), 317-324 (2006).
110. Mei L, Sun H, Jin X et al. Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm. Res. 24(5), 955-962 (2007).
111. Westedt U, Kalinowski M, Wittmar M et al. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. J. Control. Release 119 (1), 41-51 (2007).
112. Fields RC, Solan A, McDonagh KT, Niklason E, Lawson JH. Gene therapy in tissue-engineered blood vessels. Tissue Eng. 9(6), 1281-1287 (2003).
113. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 355(9199), 213-222 (2000).
114. Gaffney MM, Hynes SO, Barry F, O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br. J. Pharmacol. 152(2), 175-188 (2007).
115. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol. Ther. 15(7), 1233-1247 (2007).
116. Conte MS. Molecular engineering of vein bypass grafts. J. Vasc. Surg. 45, 74A-81A (2007).
117. Jabr-Milane, van V, Devalapally H et al. Multi-functional nanocarriers for targeted delivery of drugs and genes. J. Control. Release 130(2), 121-128 (2008).
118. Alexander JH, Hafley G, Harrington RA et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled crial. JAMA 294(19), 2446-2454 (2005).
119. Berceli SA, Hevelone ND, Lipsitz SR et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J. Vasc. Surg. 46(6), 1173-1179 (2007).
120. Conte MS, Bandyk DF, Clowes AW et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43(4), 742-751 (2006).
121. Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J. Vasc. Surg. 44(3), 633-641 (2006).
122. Luo ZY, Akita GY, Date T et al. Adenovirus-mediated expression of β-adrenergic receptor kinase C-terminus reduces intimal hyperplasia and luminal stenosis of arteriovenous polytetrafluoroethylene grafts in pigs. Circulation 111(13), 1679-1684 (2005).
123. Petrofski JA, Hata JA, Williams M et al. A Gβγ inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J. Thorac. Cardiovasc. Surg. 130(6), 1683-1690 (2005).
124. Petrofski JA, Hata JA, Gehrig, TR et al. Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia. J. Thorac. Cardiovasc. Surg. 127(1), 27-33 (2004).
125. Wolff RA, Ryomoto M, Stark VE et al. Antisense to transforming growth factor-β1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. J. Vasc. Surg. 41(3), 498-508 (2005).
126. Schepers A, Eefting D, Bonta PI et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 26(9), 2063-2069 (2006).
127. Egashira K, Nakano K, Ohtani K et al. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler. Thromb. Vasc. Biol. 27(12), 2563-2568 (2007).
128. Miyake T, Aoki M, Shiraya S et al. Inhibitory effects of NFκB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J. Mol. Cell Cardiol. 41(3), 431-440 (2006).
129. Miyake T, Aoki M, Morishita R. Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFκB and E2F in a rabbit model. Cardiovasc. Res. 79(4), 706-14 (2008).
130. Andrade JD, Hlady V. Protein adsorption and materials biocompatibility - a tutorial review and suggested hypotheses. Adv. Polymer Sci. 79, 1-63 (1986).
131. Kidane AG, Salacinski H, Tiwari A, Bruckdorfer KR, Seifalian AM. Anticoagulant and antiplatelet agents: their clinical and device application (s) together with usages to engineer surfaces. Biomacromolecules 5(3), 798-813 (2004).
132. Sarkar S, Sales KM, Hamilton G, Seifalian AM. Addressing thrombogenicity in vascular graft construction. J. Biomed. Mater. Res. B Appl. Biomater. 82(1), 100-108 (2007).
133. Devine C, Hons B, McCollum C. Heparin-bonded Dacron or polyterrafluoroethylene for femoropopliteal bypass grafting: a multicenter trial. J. Vasc. Surg. 33(3), 533-539 (2001).
134. Devine C, McCollum C. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J. Vasc. Surg. 40(5), 924-931 (2004).
135. Bosiers M, Deloose K, Verbist J et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. J. Vasc. Surg. 43(2), 313-318 (2006).
136. Verma S, Marsden PA. Nitric oxide-eluting polyurethanes-vascular grafts of the future? N. Engl. J. Med. 353(7), 730-731 (2005).
137. Ahanchi SS, Tsihlis ND, Kibbe MR. The role of nitric oxide in the pathophysiology of intimal hyperplasia. J. Vasc. Surg. 45, 64A-73A (2007).
138. Frost MC, Reynolds MM, Meyerhoff ME. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials 26(14), 1685-1693 (2005).
139. Miller MR, Megson I. Review - recent developments in nitric oxide donor drugs. Br. J. Pharmacol. 151(3), 305-321 (2007).
140. Keefer K. Biomaterials: thwarting thrombus. Nat. Mater. 2(6), 357-358 (2003).
141. Zhang H, Annich GM, Miskulin J et al. Nitric oxide-releasing fumed silica particles: synthesis, characterization, and biomedical application. J. Am. Cbem. Soc. 125(17), 5015-5024 (2003).
142. Kapadia MR, Chow W, Tsihlis ND et al. Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. J. Vasc. Surg. 47(1), 173-182 (2008).
143. Ishii Y, Sakamoto S, Kronengold RT et al. A novel bioengineered small-caliber vascular graft incorporating heparin and sirolimus: excellent 6-month patency. J. Thorac. Cardiovasc. Surg. 135(6), 1237-1245 (2008).
144. Tseng PY, Jordan SW, Sun X, Chaikof E. Catalytic efficiency of a thrombomodulin-functionalized membrane-mimetic film in a flow model. Biomaterials 27(13), 2768-2775 (2006).
145. Hashi CK, Zhu Y, Yang GY et al. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc. Natl Acad. Sci. USA 104(29), 11915-11920 (2007).
146. Chua KN, Chai C, Lee PC et al. Surface-aminated electrospun nanofibers enhance adhesion and expansion of human umbilical cord blood hematopoietic stem/progenitor cells. Biomaterials 27(36), 6043-6051 (2006).
147. Shih YR, Chen CN, Tsai SW, Wang YJ, Lee OK. Growth ofmesenchymal stem cells on electrospun type I collagen nanofibers. Stem Cells 24(11), 2391-2397 (2006).
148. Davis ME, Motion JP, Narmoneva DA et al. Injectable self-assembling peptide nanofibers create intramyocardial nucroenvironments for endothelial cells. Circulation 111(4), 442-450 (2005).
149. Carampin P, Conconi MT, Lora S et al. Electrospun polyphosphazene nanofibers for in vitro fat endothelial cells proliferation. J. Biomed. Mater. Res. A 80(3), 661-668 (2007).
150. Feng SS, Zeng W, Teng Y et al. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomed. 2(3), 333-344 (2007).
151. Varshosaz J, Soheili M. Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries. J. Microencapsul. 1-9 (2008).
152. Gou M, Li X, Dai M et al. A novel injectable local hydrophobic drug delivery system: biodegradable nanoparticles in thermo-sensitive hydrogel. Int. J. Pharm. 359(1-2), 228-33 (2008).
153. Banai S, Chorny M, Gertz SD et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 26(4), 451-461 (2005).
154. Deshpande D, Devalapally H, Amiji M. Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm. Res. (2008).
155. Cyrus T, Zhang H, Allen JS et al. Intramural delivery of rapamycin with αvβ3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler. Thromb. Vasc. Biol. 28(5), 820-826 (2008).
156. Lanza GM, Winter PM, Caruthers SD et al. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomed. 1(3), 321-329 (2006).
157. Kolodgie FD, John M, Khurana C et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106(10), 1195-1198 (2002).
158. Epstein H, Berger V, Levi I et al. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J. Control. Release 117(3), 322-332 (2007).